Ophtesia 4 mg/ml kapi za oko, otopina Chorvátsko - chorvátčina - HALMED (Agencija za lijekove i medicinske proizvode)

ophtesia 4 mg/ml kapi za oko, otopina

agepha pharma s.r.o., diaľničná cesta 5, senec, slovačka - oksibuprokainklorid - kapi za oko, otopina - urbroj: 1 ml otopine sadrži 4 mg oksibuprokainklorida

Lucentis Európska únia - chorvátčina - EMA (European Medicines Agency)

lucentis

novartis europharm limited - ranibizumab - wet macular degeneration; macular edema; diabetes complications; myopia, degenerative; choroidal neovascularization - ophthalmologicals - Луцентис prikazan kod odraslih za liječenje неоваскулярной (vlažna) senilne makularne degeneracije (amd)liječenje vida zbog хориоидальной неоваскуляризации (ХНВ)poremećaje vida zbog dijabetes pomagala макулярного edema (ДМО)poremećaje vida zbog макулярного edema sekundarne okluzije ретинальных vena (branch ili središnji glr glr).

Byooviz Európska únia - chorvátčina - EMA (European Medicines Agency)

byooviz

samsung bioepis nl b.v. - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; myopia, degenerative - ophthalmologicals - byooviz is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ximluci Európska únia - chorvátčina - EMA (European Medicines Agency)

ximluci

stada arzneimittel ag - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ximluci is indicated in adults for:the treatment of neovascular (wet) age-related macular degeneration (amd)the treatment of visual impairment due to diabetic macular oedema (dme)the treatment of proliferative diabetic retinopathy (pdr)the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)the treatment of visual impairment due to choroidal neovascularisation (cnv).

Ranivisio Európska únia - chorvátčina - EMA (European Medicines Agency)

ranivisio

midas pharma gmbh - ranibizumab - wet macular degeneration; macular edema; diabetic retinopathy; diabetes complications - ophthalmologicals - ranivisio is indicated in adults for:• the treatment of neovascular (wet) age-related macular degeneration (amd)• the treatment of visual impairment due to diabetic macular oedema (dme)• the treatment of proliferative diabetic retinopathy (pdr)• the treatment of visual impairment due to macular oedema secondary to retinal vein occlusion (branch rvo or central rvo)• the treatment of visual impairment due to choroidal neovascularisation (cnv).

LUCENTIS 10mg/ml Rastvor za injekciju Čierna Hora - chorvátčina - CInMED-Institut za ljekove i medicinska sredstva Crne Gore

lucentis 10mg/ml rastvor za injekciju

"novartis pharma services ag" dio stranog druŠtva podgorica - ranibizumab - rastvor za injekciju - 10mg/ml

Ikervis Európska únia - chorvátčina - EMA (European Medicines Agency)

ikervis

santen oy - ciklosporin - bolesti rožnice - ophthalmologicals - liječenje teške keratitisa u odraslih bolesnika s suho oko bolesti, što je oplemenjen usprkos suza zamjene.

Lapovis plus 50 mikrograma/ml + 5 mg/ml kapi za oko, otopina Chorvátsko - chorvátčina - HALMED (Agencija za lijekove i medicinske proizvode)

lapovis plus 50 mikrograma/ml + 5 mg/ml kapi za oko, otopina

zentiva k.s., u kabelovny 130, dolni mecholupy, prag 10, Češka - latanoprost timololmaleat - kapi za oko, otopina - 0,05 mg/ml + 5 mg/ml - urbroj: jedan ml otopine sadrži 50 mikrograma latanoprosta i 5 mg timolola (u obliku timololmaleata)